

## Interview Summary

Application No.

09/481,207

Applicant(s)

PHILLIPS, JEFFREY OWEN

Examiner

Jane T. Fan

Art Unit

1625

All participants (applicant, applicant's representative, PTO personnel):

(1) Jane T. Fan.(3) Dr. sharpe.(2) Mahoney.(4) Dr. Phillips.

Date of Interview: \_\_\_\_\_

Type: a) ☐ Telephonic b) ☐ Video Conference  
c) ☒ Personal [copy given to: 1) ☐ applicant 2) ☐ applicant's representative]

Exhibit shown or demonstration conducted: d) ☐ Yes e) ☐ No.

If Yes, brief description:

Claim(s) discussed: all.Identification of prior art discussed: pat'4,786,505, database IPA of STN (JP 05194225), database WPIDS of STN.Agreement with respect to the claims f) ☒ was reached. g) ☐ was not reached. h) ☐ N/A.

Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: See Continuation Sheet.

(A fuller description, if necessary, and a copy of the amendments which the examiner agreed would render the claims allowable, if available, must be attached. Also, where no copy of the amendments that would render the claims allowable is available, a summary thereof must be attached.)

i) ☐ It is not necessary for applicant to provide a separate record of the substance of the interview(if box is checked).

Unless the paragraph above has been checked, THE FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has already been filed, APPLICANT IS GIVEN ONE MONTH FROM THIS INTERVIEW DATE TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW. See Summary of Record of Interview requirements on reverse side or on attached sheet.

  
JANE FAN  
PRIMARY EXAMINER  
GROUP 1200

Examiner Note: You must sign this form unless it is an Attachment to a signed Office action.

\_\_\_\_\_  
Examiner's signature, if required

Continuation of Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: 1. Solid composition having buffer component sufficient to prevent or inhibit acid degradation of PPI by gastric acid sufficient to achieve bioavailability of the drug. Applicants will study the references to see the amount of buffer in the art references to be distinctly differentiate from the claims. Applicants will calculate and tabulate and compare the art amount of buffer and the claims'. 2. Claims will contain a Markush expression of PPI consisting of what is in claim 6 as originally filed except three compounds to be deleted. 3. Liquid composition has two new art references.( Trudeau and Quercia ). Composition should have criticality of buffer amount with respect to PPI and the source of PPI. The source of PPI in the claim is not from enteric-coated forms .